The Latest Breaking News from Pfizer

The EU’s top court annulled the Commission’s decision to deny the newspaper New York Times access to messages exchanged between President Ursula von der Leyen and Pfizer CEO Albert Bourla, finding that the EU executive failed to plausibly explain why it does not possess the texts.

A top European court says the European Commission was wrong to refuse the New York Times access to text messages sent between President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

June S&P 500 E-Mini futures (ESM25) are down -0.21%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.24% this morning, pointing to a muted open on Wall Street as investors await the latest reading on U.S. job openings and a new round of corporate earnings reports.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax

Also: 90% of earnings calls mention tariffs, China says there are no talks with Washington on trade.

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside.

Zimmer Biomet hit its 34th 52-week low on Tuesday. Its shares have decreased by over 20% in the past year. Trading at just 11.8x the 2025 EPS estimate, the maker of orthopedic medical devices looks cheap.